Summary
Health Canada has authorized RYBELSUS® as the first GLP-1 pill to reduce the risk of heart attack and stroke in adults with type 2 diabetes. While the daily pill costs approximately $2542 per patient per year, it is widely covered by provincial health plans for eligible patients who have not seen success with metformin.
In a major expansion of diabetic care, Health Canada has officially authorized RYBELSUS® (semaglutide tablets) to reduce the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death, in adults with type 2 diabetes.
While RYBELSUS® has been available since 2020 to manage blood sugar, this new authorization marks it as the first and only glucagon-like peptide-1 (GLP-1) receptor agonist in pill form proven to provide direct cardiovascular protection for high-risk patients in Canada.
Beyond Blood Sugar
Cardiovascular disease remains the second-leading cause of death in Canada, and for those living with type 2 diabetes, the risk of a life-altering heart event is significantly higher. Traditionally, cardiovascular protection in the GLP-1 class was only available via weekly injections.
The authorization is based on the results of the landmark SOUL trial, which involved over 9,600 participants. The study demonstrated that a 14 mg daily dose of oral semaglutide statistically reduced the risk of major adverse cardiovascular events (MACE) by 14% over a four-year period.
“This approval marks an important milestone for type 2 diabetes patients in Canada,” says Vince Lamanna, President of Novo Nordisk Canada Inc. “RYBELSUS is the first and only approved GLP‑1 in pill form in Canada that improves glycemic control and offers cardiovascular protection.”
Coverage and Cost
Despite being a high-demand medication, RYBELSUS® is increasingly accessible across the country. The current cost is approximately $2543 per patient per year.
For most Canadians, this cost is not paid entirely out of pocket:
- Provincial Coverage: RYBELSUS® is listed on most provincial formularies under “Limited Use” criteria for patients with type 2 diabetes.
- Private Insurance: Most private employer-based insurance plans provide coverage for RYBELSUS®, though co-pays vary.
- Patent Shifts: Interestingly, as of early 2026, the patent for some semaglutide formulations has begun to expire in Canada, paving the way for future generic versions that could further lower costs.
How to Take It
Unlike its injectable counterparts, RYBELSUS® is a daily tablet. However, its effectiveness depends on strict adherence to a specific routine: it must be taken on an empty stomach in the morning with no more than 4 ounces (half a cup) of plain water, followed by a 30-minute wait before eating or drinking anything else. If you miss a dose of RYBELSUS®, skip the missed dose and go back to your regular schedule.
By offering heart protection in a simple daily pill, Health Canada’s latest authorization provides a powerful new tool for Canadians looking to manage their diabetes while proactively defending their heart health.
Subscribe to The Health Insider newsletter for more evidence-based updates on Canadian medical breakthroughs.
~ Read more from The Health Insider ~
- Save on Ozempic: Generic Swaps Arrive in Canada
Generic Ozempic has arrived in Canada, slashing costs by two-thirds. Learn how this historic price drop benefits your health and wallet. - Nine in Ten Canadians Want the Health System to Change. Here’s What They’re Saying.A new national survey finds 91% of Canadians want health system change now, with broad openness to team-based care, digital tools, and private delivery.
- Cataract Awareness: Guard Your Eyes from UV DamageJune is Cataract Awareness Month. Learn how wearing 100% UV blocking sunglasses protects your eyes and reduces your risk of cataracts over time.
- Your Social Media Feed May Be Selling You Women’s Health Products That Don’t WorkWomen’s health gaps are being filled by viral marketing. Here is the clinical reality behind 5 heavily promoted online wellness trends.
- Ditching your Sunscreen? Separate Fact From FictionTrading sunscreen for internet rumours exposes your skin to a proven Class 1 carcinogen — the sun. Read the risk analysis and learn about new options before heading outside.
- Would You Trust AI Over Your Doctor?Nearly half of Canadians use AI for medical advice, but 68% would still wait two weeks for a human doctor over an immediate AI diagnosis.
The information provided on TheHealthInsider.ca is for educational purposes only and does not substitute for professional medical advice. TheHealthInsider.ca advises consulting a medical professional or healthcare provider when seeking medical advice, diagnoses, or treatment. To read about our editorial review process click here.
